ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Overall survival benefits provided by lenalidomide maintenance after chimeric antigen receptor T cell therapy in patients with refractory/relapsed diffuse large B-cell lymphoma

Ping, Nana; Qu, Changju; Li, Mengyun; Kang, Liqing; Kong, Danqin; Chen, Xiaochen; Wu, Qian; Xia, Fan; Yu, Lei; Yao, Hong; Yan, Lingzhi; Wu, Depei*; Jin, Zhengming*苏州大学; 1
Annals of Translational Medicine2022-3DOI: 10.21037/atm-22-20
4被引5阅读
引用收藏
分享

摘要

Background: Chimeric antigen receptor T cell (CAR-T) therapy has achieved remarkable effects in refractory/relapsed (R/R) diffuse large B-cell lymphoma (DLBCL). However, many patients receiving CAR-T therapy still eventually die of disease recurrence or progression due to target antigen loss or exhaustion of CAR-T cells. Therefore, maintaining the efficacy of CAR-T has become a particular research focus. As lenalidomide can regulate T cell function, we conducted a study to evaluate the efficacy of lenalidomide maintenance after CAR-T therapy in R/R DLBCL patients. @@@ Methods: Seven R/R DLBCL patients who received lenalidomide maintenance after CAR-T therapy and nine DLBCL patients that underwent CAR-T treatment alone were included. The clinical data of all subjects were collected to evaluate the efficacy of lenalidomide maintenance. In order to understand the possible mechanisms of lenalidomide in CAR-T therapy, CAR-T copies of peripheral blood were regularly detected by quantitative real-time polymerase chain reaction, and an in vitro test was also conducted. @@@ Results: Overall survival (OS) was significantly prolonged in the lenalidomide maintenance group. Furthermore, one case responding to CAR-T therapy initially but suffering a relapse shortly achieved complete remission again after lenalidomide exposure, with an increase in the number of CAR-T copies detected. The in vitro test showed that lenalidomide could delay the exhaustion of CAR-T cells. @@@ Conclusions: Lenalidomide maintenance after CAR-T therapy is a safe and effective choice for R/R DLBCL patients. We confirmed that lenalidomide maintenance can improve patients' OS, and the delayed exhaustion of CAR-T cells may contribute to this OS benefit.

学科与关键词

关键词
Refractory/relapsed (R/R)diffuse large B-cell lymphoma (DLBCL)chimeric antigen receptor T cell (CAR-T)lenalidomide
相关
加载中…
  • Decitabine-primed tandem CD19/CD22 CAR-T therapy in relapsed/refractory diffuse large B-cell lymphoma patients
    Qu, Changju*; Zou, Rui; Wang, Peng; Zhu, Qian; Kang, Liqing; Ping, Nana; Xia, Fan; Liu, Hailing; Kong, Danqing; Yu, Lei; Wu, Depei*; Jin, Zhengming*Frontiers in Immunology, 2022, 13: 969660.被引 8
  • CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma
    Cheng, Qian; Tan, Jingwen; Liu, Rui; Kang, Liqing; Zhang, Yi; Wang, Erhua; Li, Ying; Zhang, Jian; Xiao, Han; Xu, Nan; Li, Minghao; Yu, Lei*; Li, Xin*CYTOTHERAPY, 2022, 24(10): 1026-1034.被引 9
  • The Addition of Lenalidomide to R-CHOP Is Effective for Prevention of CNS Relapse in High-Risk Patients with Diffuse Large B-Cell Lymphoma
    Wei, Xiaolei; Guo, Xutao; Wei, Qi; Xiong, Dan; Zhang, Peng; Zhang, Zewen; Wei, Yongqiang; Feng, Ru65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
查看全部 →

发表信息

论文状态
公开发表
期刊
Annals of Translational Medicine
发表日期
2022-03
卷期
第 10 卷, 第 6 期
DOI
10.21037/atm-22-20
期刊等级
4区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81400112, 81400155, 81600114]; National Key R&D Program of China [2016YFC0902800]; Natural Science Foundation of Jiangsu Province [BK20160342, BK20140374]; Top-notch Young Health Talents, 5th Suzhou Health Professionals Program [GSWS2019035]; National Clinical Research Center for Blood Diseases Program [2021ZKMC01, 2021ZKMB03]

作者

  • P

    Ping, Nana (第一作者)

    1 · soochow univ

  • Q

    Qu, Changju

    1 · soochow univ

查看全部 13 位作者收起作者
  • L

    Li, Mengyun

    1 · soochow univ

  • K

    Kang, Liqing

  • K

    Kong, Danqin

    1 · soochow univ

  • C

    Chen, Xiaochen

    1 · soochow univ

  • W

    Wu, Qian

    1 · soochow univ

  • X

    Xia, Fan

    1 · soochow univ

  • Y

    Yu, Lei

  • Y

    Yao, Hong

    1 · soochow univ

  • Y

    Yan, Lingzhi

    1 · soochow univ

  • W

    Wu, Depei (通讯)

    1 · soochow univ

  • J

    Jin, Zhengming (通讯)

    1 · soochow univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417